Multiplex Immune Marker Panel Studies - Learn - PLCO

Purpose

Throughout the Etiologic and Early Marker Studies (EEMS) existence, several studies have measured various immune markers in blood serum. For CDAS, these measurements are available in separate datasets corresponding to each study for which they were originally selected.

Population

These studies were each selected at different time points, using a different set of exclusions and matching criteria. For all studies, the common requirements for inclusion were etiologic consent, pre-diagnostic serum availability, intervention arm, a baseline questionnaire, some form of follow-up within the trial, and no history of the site-specific cancer prior to blood collection. For all non-pilot studies, the set of cases were matched directly to the controls. Matching was done at a 1:1 ratio, except for never-smokers in the lung studies, in which never-smoking controls were matched to never-smoking cases at a 3:1 ratio. The second lung study is a replication of the first using completely different cases and controls. Time on study was not considered in the matching for the NHL and Ovarian studies.

Site	Non-Common Inclusion Criteria	Matching Variables	Cases	Non-Cases
Lung	Defined Smoking History	Gender Age at Randomization (5 Years) Year of Randomization Smoking History Study Year of Dx/Selection	527	592
NHL	No Cancer at Baseline	Gender Age at Randomization (5 Years) Year of Randomization Study Center Year and Season of Entry (4 Months)	301	301
Ovarian	Females Controls Cancer-free through Follow-up No Cancer Prior to DX/Selection No Oophorectomies in Controls	Race Age at Randomization (5 Years) Year and Season of Blood Draw (3 Months) Study Year of Blood Draw Time of Day of Blood Draw (am/pm)	150	149
Pilot (controls only)	No Cancer at Baseline Cancer-free through Follow-up Confirmed Dead	N/A	N/A	100
2^nd Pilot (controls only)	No Cancer at Baseline Cancer-free through Follow-up Confirmed Dead Not in any EEMS Studies Has Less than 3 Years of Follow-up Time	N/A	N/A	54
2^nd Lung	Defined Smoking History Not in First MIP Lung Study	Gender Age at Randomization (5 Years) Year of Blood Draw (2 Years) Study Year of Blood Draw Smoking History Study Year of Dx/Selection	526	625
Endometrial	Females No American Indians or Missing Race No Cancer at Baseline Controls Cancer-free through Follow-up No Cancer Prior to DX/Selection No Hysterectomy	Race Age at Randomization (5 Years) Fiscal Year of Randomization (2 Years) Study Year of Blood Draw Study Year of Dx/Selection	284	284
Upper GI	No Cancer at Baseline Males Only among Gastric Cases	Gender Race Age at Blood Draw (+/- 1 Year) Year of Blood Draw Study Year of Blood Draw Time of Day of Blood Draw (am/pm) Number of Days on Study	63	63

Data Collected

Below is a table of the analytes measured in each study. All measures are presented in pg/mL.

	Lung	NHL	Ovarian	Pilot	2^nd Pilot	2^nd Lung	Endometrial	Upper GI
Adiponectin							X	X
Adipsin							X	X
Amylin		X	X	X	X
Basic Fibroblast Growth Factor	X	X	X	X	X	X	X	X
B-Cell Attracting Chemokine 1	X	X		X	X	X	X	X
C-C motif chemokine ligand 1			X
Chemokine Ligand 10	X	X	X	X	X	X	X	X
Chemokine Ligand 11	X	X		X	X	X	X	X
Chemokine Ligand 12	X	X		X	X	X	X	X
Chemokine Ligand 13	X	X		X	X	X	X	X
Chemokine Ligand 19	X	X		X	X	X	X	X
Chemokine Ligand 2	X	X	X	X	X	X	X	X
Chemokine Ligand 20	X	X		X	X	X	X	X
Chemokine Ligand 21	X	X		X	X	X	X	X
Chemokine Ligand 22	X	X	X	X	X	X	X	X
Chemokine Ligand 27	X	X		X	X	X	X	X
Chemokine Ligand 5	X	X		X	X	X	X	X
Chemokine Ligand 6	X	X		X	X	X	X	X
Chemokine Ligand 7	X	X	X	X	X
Chemokine Ligand 8	X	X		X	X	X	X	X
Chemokine Ligand 9	X	X		X	X	X	X	X
C-peptide		X	X	X	X
C-Reactive Protein	X		X	X	X	X	X	X
C-X3-C motif chemokine ligand 1	X	X	X	X	X			X
C-X-C motif chemokine ligand 1	X	X	X	X	X	X	X	X
Eotaxin	X	X	X	X	X	X	X	X
Eotaxin-2	X	X		X	X	X	X	X
Eotaxin-3				X
Epidermal Growth Factor	X	X	X	X	X	X	X	X
Epidermal Growth Factor Receptor	X	X	X	X	X	X	X	X
Fms-related tyrosine kinase 3 ligand	X	X	X	X	X
Gastric inhibitory polypeptide		X	X	X	X
Ghrelin				X
Glucagon		X	X	X	X
Glucagon-like peptide-1		X	X	X	X
Granulocyte colony-stimulating factor	X	X	X	X	X	X	X	X
Granulocyte-macrophage colony-stimulating factor	X	X	X	X				X
Insulin		X	X	X	X
Interferon alpha-2	X	X	X	X	X
Interferon-gamma	X	X	X	X	X
Interleukin 1	X	X	X	X	X	X	X	X
Interleukin 1 alpha	X	X	X	X	X
Interleukin 1 beta	X	X	X	X				X
Interleukin 1 Receptor Antagonist	X	X	X	X		X	X	X
Interleukin 10	X	X	X	X				X
Interleukin 11	X	X		X	X
Interleukin 12 p40	X	X	X	X	X
Interleukin 12 p70	X	X	X	X				X
Interleukin 13				X				X
Interleukin 15	X	X	X	X
Interleukin 16	X	X		X	X	X	X	X
Interleukin 17	X	X	X	X				X
Interleukin 2	X	X	X	X
Interleukin 20				X
Interleukin 21				X				X
Interleukin 23				X				X
Interleukin 28 alpha				X
Interleukin 29 Interferon Lambda 1	X	X		X	X	X	X	X
Interleukin 3	X	X	X	X		X	X	X
Interleukin 33	X	X		X	X	X	X	X
Interleukin 4	X	X	X	X				X
Interleukin 5	X	X	X	X				X
Interleukin 6	X	X	X	X				X
Interleukin 7	X	X	X	X		X	X	X
Interleukin 8	X	X	X	X	X	X	X	X
Interleukin 9				X
Leptin		X	X	X	X
Leukemia Inhibitory Factor	X	X		X	X
Lipocalin-2							X	X
Macrophage colony-stimulating factor				X
Macrophage inflammatory protein 1 alpha	X	X	X	X	X			X
Macrophage inflammatory protein 1 beta	X	X	X	X	X	X	X	X
Macrophage inflammatory protein 1 delta	X	X		X	X	X	X	X
Pancreatic Polipeptide		X	X	X	X
Pancreatic Polipeptide YY		X	X	X	X
Plasminogen activator inhibitor-1							X	X
Resistin							X	X
Serum Amyloid A	X			X	X	X	X	X
Serum Amyloid P	X			X	X	X	X	X
Soluble Interleukin 1 Receptor Type 1	X	X	X	X	X
Soluble Interleukin 2 Receptor Alpha	X	X	X	X
Soluble Interleukin 4 Receptor	X	X	X	X	X	X	X	X
Soluble Interleukin 6 beta	X	X	X	X	X	X	X	X
Soluble Interleukin 6 Receptor	X	X	X	X	X	X	X	X
Soluble Receptor for Advanced Glycation Endproducts	X	X	X	X	X
Soluble Tumor Necrosis Factor Receptor I	X	X	X	X	X	X	X	X
Soluble Tumor Necrosis Factor Receptor II	X	X	X	X	X	X	X	X
Stem Cell Factor	X	X		X	X	X	X	X
Thrombopoietin	X	X		X	X	X	X	X
Thymic Stromal Lymphopoietin	X	X		X	X	X	X	X
Thymus and Activation Regulated Chemokine	X	X		X	X	X	X	X
Transforming Growth Factor Alpha	X	X	X	X		X	X	X
Transforming growth factor beta 1							X
Tumor Necrosis Factor Alpha 1	X	X	X	X	X	X	X	X
Tumor Necrosis Factor Beta	X	X	X	X		X	X	X
Tumor Necrosis Factor Receptor Superfamily, Member 10	X	X		X	X	X	X	X
Tumor Necrosis Factor Receptor Superfamily, Member 5	X	X	X	X	X
Tumor Necrosis Factor Receptor Superfamily, Member 8	X	X	X	X	X
Vascular Endothelial Growth Factor	X	X	X	X	X	X	X	X
Vascular endothelial growth factor receptor 1	X	X	X	X	X
Vascular endothelial growth factor receptor 2	X	X	X	X	X	X	X	X
Vascular endothelial growth factor receptor 3	X	X	X	X	X	X	X	X
X-C motif chemokine ligand 1				X

Multiplex Immune Marker Panel Studies data can be obtained in the MIPS datasets

Main Findings

Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study.
Chaturvedi AK, Kemp TJ, Pfeiffer RM, Biancotto A, Williams M, Munuo S, Purdue MP, Hsing AW, Pinto L, McCoy JP, Hildesheim A
Cancer Epidemiol. Biomarkers Prev. 2011 Sep; Volume 20 (Issue 9): Pages 1902-11 PUBMED
Circulating markers of interstitial lung disease and subsequent risk of lung cancer.
Shiels MS, Chaturvedi AK, Katki HA, Gochuico BR, Caporaso NE, Engels EA
Cancer Epidemiol. Biomarkers Prev. 2011 Oct; Volume 20 (Issue 10): Pages 2262-72 PUBMED
Invited commentary: circulating inflammation markers and cancer risk--implications for epidemiologic studies.
Chaturvedi AK, Moore SC, Hildesheim A
Am. J. Epidemiol. 2013 Jan; Volume 177 (Issue 1): Pages 14-9 PUBMED
A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.
Purdue MP, Hofmann JN, Kemp TJ, Chaturvedi AK, Lan Q, Park JH, Pfeiffer RM, Hildesheim A, Pinto LA, Rothman N
Blood. 2013 Aug; Volume 122 (Issue 6): Pages 951-7 PUBMED
Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
Trabert B, Pinto L, Hartge P, Kemp T, Black A, Sherman ME, Brinton LA, Pfeiffer RM, Shiels MS, Chaturvedi AK, Hildesheim A, Wentzensen N
Gynecol. Oncol. 2014 Nov; Volume 135 (Issue 2): Pages 297-304 PUBMED
Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.
Shiels MS, Katki HA, Hildesheim A, Pfeiffer RM, Engels EA, Williams M, Kemp TJ, Caporaso NE, Pinto LA, Chaturvedi AK
J. Natl. Cancer Inst. 2015 Oct; Volume 107 (Issue 10) PUBMED
Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
Trabert B, Eldridge RC, Pfeiffer RM, Shiels MS, Kemp TJ, Guillemette C, Hartge P, Sherman ME, Brinton LA, Black A, Chaturvedi AK, Hildesheim A, Berndt SI, Safaeian M, Pinto L, Wentzensen N
Int. J. Cancer. 2017 Feb; Volume 140 (Issue 3): Pages 600-610 PUBMED
Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium.
Cook MB, Barnett MJ, Bock CH, Cross AJ, Goodman PJ, Goodman GE, Haiman CA, Khaw KT, McCullough ML, Newton CC, Boutron-Ruault MC, Lund E, Rutegård M, Thornquist MD, Spriggs M, Giffen C, Freedman ND, Kemp T, Kroenke CH, Le Marchand L, ...show more Park JY, Simon M, Wilkens LR, Pinto L, Hildesheim A, Campbell PT
Gut. 2018 Aug PUBMED